Overview

Also Known As: Tsc1 flox, Tsc1^c

These floxed mutant mice possess loxP sites flanking exons 17 and 18 of the Tsc1 gene. This mutant strain may be useful in tissue-specific studies including tuberous sclerosis or other hamartoma syndromes, regulation of the actin cytoskeleton and motility, cellular and organismal glucose homeostasis, cell growth responses, apoptosis regulation, and regulation of cell size.

Donating Investigator

David J. Kwiatkowski, Brigham and Women's Hospital

Genetic overview

Genetic Background	Generation
	F?+pN1F17 (2019-03-18 00:00:00)

Tsc1^tm1Djk

Allele Type	Gene Symbol	Gene Name
Targeted (Conditional ready (e.g. floxed), No functional change)	Tsc1	tuberous sclerosis 1

View Genetics

Research Applications

Research Tools

View All Research Applications

Base Price

Starting at:

$255.00 Domestic price for female

View Price List

Details

Detailed Description

Homozygous mice are viable, fertile, normal in size, have normal expression of hamartin (the targeted gene's protein product), have no growth or behavioral defects, and are devoid of tumors through age 18 months. This mutant carries a "floxed" allele of the endogenous gene. When combined with a mutant carrying a Cre recombinase gene under the control of a promoter of interest, exons 17 and 18 of Tsc1 are deleted in the tissue of interest. This mutant may be useful in many tissue-specific studies including tuberous sclerosis or other hamartoma syndromes, regulation of the actin cytoskeleton and motility, cellular and organismal glucose homeostasis, cell growth responses, apoptosis regulation, and regulation of cell size.

When bred to a strain expressing Cre recombinase in neuronal cells (see Stock No. 003966 for example), this mutant mouse strain may be useful in studies of tuberous sclerosis.

When bred to a strain expressing Cre recombinase in oocytes of the primordial follicles (see Stock No. 011062 for example), this mutant mouse strain may be useful in studies of primordial follicle quiescence and activation.

When bred to a strain expressing Cre recombinase in liver (see Stock No. 003574 for example), this mutant mouse strain may be useful in studies of hepatic lipid metabolism.

Importation of this model was supported by the Tuberous Sclerosis Alliance.

Development

A targeting vector containing a loxP-flanked neomycin resistance-thymidine kinase gene cassette preceding exon 17 and a third loxP site downstream of exon 18 was electroporated into 129S4/SvJae derived J1 embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6J blastocysts. Chimeric mice were backcrossed for germ-line transmission to C57BL/6J, BALB/cJ, or 129/SvJae mice. The resulting heterozygotes were intercrossed to produce homozygotes on a mixed background.

Control Suggestions

None Available

Additional Information

Considerations for Choosing Controls

Selected References

Kwiatkowski DJ; Zhang H; Bandura JL; Heiberger KM; Glogauer M; el-Hashemite N; Onda H. 2002. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 11(5):525-34PubMed: 11875047 MGI: J:75243

View All References

Genetics

Tsc1^tm1Djk

Allele Symbol: Tsc1^tm1Djk

Allele Name	targeted mutation 1, David J Kwiatkowski
Allele Type	Targeted (Conditional ready (e.g. floxed), No functional change)
Allele Synonym(s)	Tsc1^tm1Djk; targeted mutation 1, David J Kwiatkowski
Gene Symbol and Name	Tsc1, tuberous sclerosis 1
Gene Synonym(s)	TSC; hamartin; LAM
Strain of Origin	129S4/SvJae
Chromosome	2
General Note	Phenotypic Similarity to Human Syndrome: Angiosarcoma/Lymphangiosarcoma J: 231316.
Molecular Note	A floxed neo-TK cassette was inserted into the intron preceding exon 17 and a third loxP site was introduced downstream of exon 18 by homologous recombination.
Mutations Made By	David Kwiatkowski, Brigham and Women's Hospital

Disease/Phenotype

Disease Terms

Model with phenotypic similarity to human disease where etiologies are distinct. Human genes are associated with this disease. Orthologs of these genes do not appear in the mouse genotype(s).

autistic disorder

Models with phenotypic similarity to human diseases where etiology is unknown or involving genes where ortholog is unknown.

tuberous sclerosis

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Research Tools
- Cancer Research
  - Hamartoma Syndromes
- Cre-lox System
  - loxP-flanked Sequences

Mammalian Phenotype Terms by Genotype

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Tsc1^tm1Djk/Tsc1^tm1.1Djk Tg(Syn1-cre)671Jxm/0
involves: 129S4/SvJae * C57BL/6 * CBA

behavior/neurological phenotype

abnormal involuntary movement
- clasping behavior and tremor are significantly ameliorated by rapamycin/RAD001 treatment relative to untreated animals at 30, 60, and 100 days postnatal

abnormal limb posture
- at death, usually in third to fifth postnatal week, mice are found with extensor posture of fore- and hindlimbs

hunched posture
- develops by by third or fourth postnatal week

hyperactivity
- apparent by P10

hypoactivity
- mice show progressive decline in activity with limited mobility by third or fourth postnatal week

increased startle reflex
- apparent by P10

limb grasping
- display posterior limb-clasping behavior when lifted by tail

seizures
- after P21, suspension by the tail results in gentle spinning leading severe seizure activity, followed by bradycardia and death
- mice develop clinical seizures, spontaneous and some provoked in most part by physical simulation; both types of seizures are mild or severe
- severe seizures are characterized by brief behavioral arrest, followed by several seconds of clonic activity, followed by tonic extensor posturing of trunk and limbs for 15-45 seconds

sporadic seizures
- only mild seizures occur spontaneously, characterized by brief myoclonic jerking of head and torso

straub tail
- tail dorsiflexion is exhibited

tremors
- progressive high-frequency trunk and limb tremor apparent by P10

cellular phenotype

abnormal neuron differentiation
- in mutant brains, neurons appear to be still actively growing after P14-21, whereas wild-type neurons have stopped growing
- this may result in the hypomyelination, due to secondary myelination failure

growth/size/body region phenotype

slow postnatal weight gain
- after P5 until death, mutants fail to gain weight at same rate as controls; average maximum weight is 10 grams

mortality/aging

premature death
- discontinuation of drug treatment at P30 results in clinical symptom improvement for 1-2 weeks followed by clinical deterioration and death at 79 days for rapamycin-treated and 77 days for RAD001-treated mutants
- median survival of 35 days, with no survivors beyond 65 days
- mice treated with rapamycin or RAD001 (mTOR inhibitor) show 90-100% survival to 80 days of age compared to median survival of 33 days for untreated mutants

nervous system phenotype

abnormal brain morphology
- enlarged cells are seen outside cerebral cortex, in other parts of brain including thalamus, hypothalamus and brainstem
- Normal - no increased cell loss or degeneration is observed in regions containing anomalous enlarged cells

abnormal brain wave pattern
- interictal (seizure) 1-2 second bursts of high-amplitude 7-8 hertz spikes are observed with high frequency compared with controls; these are without obvious clinical correlate
- mice aged P21-48 display 3 types of electrographic abnormalities: short spike bursts observed in all mice examined, occasionally spontaneous period of desynchronization with electrodecrement and at low incidence, frequent high-amplitude sharp waves

abnormal cerebral cortex morphology
- laminar organization is less distinct than in the 6 cortical layers of controls
- mild cortical disorganization is observed in mutants with or without rapamycin treatment
- mutants display subset of enlarged pS6-positive cells at base of cortex and in cortical layer V; drug treatment results in marked reduction in size of enlarged cells
- unusually large cells are observed in all six layers in mutants, particularly in layer V; layer of enlarged cells is seen at gray-white matter border throughout cerebral cortex at P21

abnormal dendrite morphology
- in hippocampal neuron cultures, neuronal dendritic spine density is reduced >20% compared to controls
- with rapamycin treatment, spine density is marginally increased; spine length however is increased 9% compared to treated and untreated controls or untreated mutants

abnormal dentate gyrus morphology
- enlarged cells are observed in hilus

abnormal hippocampus pyramidal cell layer
- enlarged cells are seen throughout pyramidal cell layer, particularly in CA3 region

abnormal hippocampus region morphology
- enlarged ectopic cells are seen outside the CA1-CA3 fields in stratum oriens and stratum radiatum

abnormal myelination
- hypomyelination is observed in brains of mutants
- myelination particularly in cortex is impaired due to decreased myelin production by oligodendrocytes; rapamycin treatment works to restore myelination throughout brain with greatest improvement in cortex and hippocampus
- Normal - oligodendrocyte number and distribution appears similar to wild-type

abnormal neocortex morphology
- contains some enlarged cells

abnormal neuron differentiation
- in mutant brains, neurons appear to be still actively growing after P14-21, whereas wild-type neurons have stopped growing
- this may result in the hypomyelination, due to secondary myelination failure

abnormal neuron morphology
- d at P7 does not significantly decrease abnormally oriented dendrite percentage
- in somatosensory cortex, layer V neurons often have major dendrites extending tangentially and diagonally to the pia, in contrast to control neurons which mainly have long apical dendrite oriented directly toward pial surface; rapamycin treatment initiated at P7 does not significantly decrease abnormally oriented dendrite percentage
- many pyramidal neurons demonstrate dysplastic features including increased size and thicker dendritic arbors compared to control neurons
- Nissl bodies and filamentous aggregates are often detected in enlarged neurons, prominently in brainstem but rarely in enlarged cortical cells
- population of neurons in lateral somatosensory cortex are considerably enlarged compared with those in controls; size is significantly reduced after drug treatment (from 1.8-fold to 1.2-fold), but effect reverses when treatment is stopped
- some neurons are aberrantly localized outside primary pyramidal cell layers; ectopic neurons are isolated, not organized into clusters or columns
- some neurons in somatosensory cortex show 60% increase in soma size relative to controls

increased brain weight
- brain weight to body weight ratio is significantly greater (2.4-fold) in mutants compared to wild-type; with rapamycin/RAD001 treatment, difference from control is significantly reduced but still observed

seizures
- after P21, suspension by the tail results in gentle spinning leading severe seizure activity, followed by bradycardia and death
- mice develop clinical seizures, spontaneous and some provoked in most part by physical simulation; both types of seizures are mild or severe
- severe seizures are characterized by brief behavioral arrest, followed by several seconds of clonic activity, followed by tonic extensor posturing of trunk and limbs for 15-45 seconds

sporadic seizures
- only mild seizures occur spontaneously, characterized by brief myoclonic jerking of head and torso

skeleton phenotype

abnormal spine curvature
- kyphosis is significantly improved in rapamycin/RAD001-treated mice compared with untreated mutants

Genotype: Tsc1^tm1Djk/Tsc1^tm1Djk Tg(Syn1-cre)671Jxm/0
involves: 129S4/SvJae * C57BL/6 * CBA

behavior/neurological phenotype

abnormal behavior

growth/size/body region phenotype

abnormal body size

mortality/aging

premature death
- Tg(Syn1-cre)671Jxm conditional mutants; however no data are presented
- clinical features, survival, and brain pathology are stated to be identical to that of Tsc1^tm1Djk Tsc1^tm1.1Djk Tg(Syn1-cre)671Jxm conditional mutants; however no data are presented

nervous system phenotype

abnormal nervous system morphology

abnormal nervous system physiology

Genotype: Tsc1^tm1Djk/Tsc1^tm1Djk
involves: 129S4/SvJae * C57BL/6

behavior/neurological phenotype

hypoactivity
- in fasted cre injected mice

homeostasis/metabolism phenotype

decreased body temperature
- in fasted cre injected mice

decreased circulating ketone body level
- markedly lower serum ketones in young fasted cre injected mice but not in aged fasted cre injected mice

liver/biliary system phenotype

abnormal hepatocyte morphology
- increase in hepatocyte size following adenoviral cre retro-orbital injection

abnormal liver physiology
- cre injected mice are unable to generate ketones when given sodium octanoate
- decrease in liver protein content following adenoviral cre retro-orbital injection
- in cre injected mice, the liver is largely refractory to fast induced shrinkage

enlarged liver
- about a 40% increase in liver mass following adenoviral cre retro-orbital injection

Genotype: Tsc1^tm1Djk/Tsc1^tm1Djk Tg(Gdf9-icre)5092Coo/?
involves: 129S4/SvJae * C57BL/6J

endocrine/exocrine gland phenotype

abnormal ovarian follicle morphology
- injection with rapamycin reverses the overactivation of primordial follicles, indicative that mTORC1 activity is responsible for increased activation of follicles
- mutants exhibit premature activation of the entire primordial follicle pool by P23, leading to follicle depletion and premature ovarian failure in early adulthood (2-3 months of age)

homeostasis/metabolism phenotype

increased circulating follicle stimulating hormone level
- higher levels at 3-4 months of age

increased circulating luteinizing hormone level
- higher levels at 3-4 months of age

reproductive system phenotype

abnormal ovarian follicle morphology
- injection with rapamycin reverses the overactivation of primordial follicles, indicative that mTORC1 activity is responsible for increased activation of follicles
- mutants exhibit premature activation of the entire primordial follicle pool by P23, leading to follicle depletion and premature ovarian failure in early adulthood (2-3 months of age)

reduced female fertility
- from 6-27 weeks of age, females produce at most 2 litters of normal size and then become infertile after around 12-13 weeks

Genotype: Tsc1^tm1Djk/Tsc1^tm1Djk Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
involves: 129S4/SvJae * C57BL/6 * DBA

homeostasis/metabolism phenotype

abnormal homeostasis
- gene expression analysis indicates that fat utilization and glucose production are promoted in mutants

decreased circulating triglyceride level
- mutants do not show an increase in plasma triglyceride levels in response to the high-fat diet as is seen in wild-type mice
- plasma triglyceride levels are lower than in wild-type mice, however adiponectin and leptin levels are no different

impaired glucose tolerance
- mutants exhibit mild but significant glucose intolerance

insulin resistance
- Normal - however, fasting plasma glucose and insulin levels are normal
- insulin levels at 30 minutes following glucose administration are higher in mutants than controls, indicating insulin resistance
- mutants exhibit a slight reduction in systemic insulin sensitivity

mammalian phenotype

liver/biliary system phenotype
- Normal - mutants normally do not exhibit hepatic steatosis, however when fed a high-fat diet and treated with rapamycin, they develop steatosis and show increased levels of hepatic triglycerides

liver/biliary system phenotype

abnormal hepatocyte morphology
- increase in hepatocyte cell size

abnormal hepatocyte physiology
- hepatocytes are resistant to steatosis induced by a high-fat diet

enlarged liver
- mutants develop hepatomegaly

Genotype: Tsc1^tm1Djk/Tsc1^tm1Djk
involves: 129S4/SvJae

mammalian phenotype

neoplasm
- Normal - mice do not develop mesothelioma following injection of adenovirus expressing Cre into the bladder or intraperitoneally at 2-3 months of age

Genotype: Tsc1^tm1Djk/Tsc1⁺ Tg(Pcp2-cre)2Mpin/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/cJ * C57BL/6J

behavior/neurological phenotype

abnormal response to novel odor
- Normal - however, mice show normal investigation of non-social olfactory cues
- mice show reduced investigation of social odors compared with controls, suggesting impaired discrimination of social olfactory cues

abnormal sexual interaction
- mice show impaired male-female social interactions, with reductions in the time that mice spend interacting compared to controls

abnormal social investigation
- in a 3-chambered assay of social approach and preference for social novelty, mice exhibit social impairments, showing no differences between the time spend in the chamber or in interaction with the novel mouse versus the novel object unlike controls
- in a social novelty paradigm, mice show no preference for social novelty

excessive vocalization
- P5-P12 pups show increased vocalizations

increased grooming behavior
- increase in self-grooming rates

nervous system phenotype

abnormal nervous system physiology
- despite receiving normal functioning synaptic inputs, the output of the cerebellar cortex is reduced, both tonically and in response to incoming excitatory drive
- injection of small hyperpolarizing currents results in smaller voltage changes in Purkinje cells, indicating a decrease in the effective input resistance
- Purkinje cell excitability is reduced, with Purkinje cells showing lower, graded spontaneous spiking rate, and current injection evokes fewer action potentials in Purkinje cells

abnormal Purkinje cell dendrite morphology
- increase in spine density on Purkinje cell dendrites

Genotype: Tsc1^tm1Djk/Tsc1^tm1Djk Tg(Pcp2-cre)2Mpin/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/cJ * C57BL/6J

behavior/neurological phenotype

abnormal learning/memory/conditioning
- mice exhibit similar acquisition learning of a submerged escape-platform location compared to controls, however when the escape platform location is reversed, mutants show impaired learning of the new platform location
- rapamycin treatment prevents the reversal learning impairment

abnormal response to novel odor
- Normal - however, mice show normal investigation of non-social olfactory cues
- mice show reduced investigation of social odors compared with controls, suggesting impaired discrimination of social olfactory cues

abnormal sexual interaction
- mice show impaired male-female social interactions, with reductions in the time that mice spend interacting compared to controls

abnormal social investigation
- in a 3-chambered assay of social approach and preference for social novelty, mice show social impairments, showing no differences between the time spend in the chamber or in interaction with the novel mouse versus the novel object
- in a social novelty paradigm, mice show no preference for social novelty
- treatment with rapamycin results in normal social behavior

ataxia
- mice show decreased stride length and increased stride width at 4 months of age
- mutants show initial signs of ataxia at 7-8 weeks of age which progresses with age
- rapamycin treated mutants do not show ataxic gait

excessive vocalization
- P5-P12 pups show increased vocalizations

impaired coordination
- mutants show impaired motor learning on the accelerating rotarod test before ataxia onset
- treatment with rapamycin prevents the motor phenotypes

increased grooming behavior
- increase in self-grooming rates

short stride length

nervous system phenotype

abnormal cerebellar Purkinje cell layer
- cerebellar Purkinje cell layer is abnormal with increased soma area and reduced Purkinje cell numbers
- treatment with rapamycin starting at P7 prevents the Purkinje cell defects

abnormal nervous system physiology
- despite receiving normal functioning synaptic inputs, the output of the cerebellar cortex is reduced, both tonically and in response to incoming excitatory drive
- Normal - however, alterations in synaptic transmission are not apparent in mutants
- injection of small hyperpolarizing currents results in smaller voltage changes in Purkinje cells, indicating a decrease in the effective input resistance
- Purkinje cell excitability is reduced, with Purkinje cells showing lower, graded spontaneous spiking rate, and current injection evokes fewer action potentials in Purkinje cells

abnormal Purkinje cell dendrite morphology
- increase in spine density on Purkinje cell dendrites

abnormal Purkinje cell morphology
- markers for endoplasmic reticulum and oxidative stress are elevated indicating elevated neuronal stress of Purkinje cells
- Purkinje cell soma area is increased at 4 weeks of age
- Purkinje cells display abnormal axonal projections with numerous protrusions and abnormal collateralization

decreased Purkinje cell number
- an increase in Purkinje cell apoptosis is seen at 7-8 weeks of age
- decrease in Purkinje cell numbers are first seen at 2 months of age, with a further reduction at 4 months

References

Kwiatkowski DJ; Zhang H; Bandura JL; Heiberger KM; Glogauer M; el-Hashemite N; Onda H. 2002. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 11(5):525-34PubMed: 11875047 MGI: J:75243

Additional - Tsc1^tm1Djk related

Technical Support

Contact Technical Support

Genotyping Protocols
- Standard PCR: Tsc1^tm1Djk
- Genotyping resources and troubleshooting
Dietary Information
- LabDiet® 5K52 formulation (6% fat)
Breeding Considerations

When maintaining a live colony, these mice are maintained as homozygotes.
- Additional Breeding and Husbandry Support
Mating System
- Homozygote x Homozygote
Citation
When using the Tsc1^c mouse strain in a publication, please cite the originating article(s) and include JAX stock #005680 in your Materials and Methods section.

Animal Health Reports

Facility Barrier Level Descriptions

AX10 (Standard)

Pricing & Availability

Repository Live

Domestic
International

Live Mouse

Age

Genotype

Price

weeks

Cryorecovery - Pricing

Service	Genotype	Price
	Heterozygous for Tsc1<tm1Djk>

We will fulfill your order by providing at least two carriers for each strain ordered. The total number, sex, and genotypes provided will vary, although typically 8 or more animals are provided. Please check genotypes which will be recovered. While the genotypes of all animals produced will be communicated to you prior to scheduling shipment, the genotypes of animals provided may not reflect the mating scheme and genotypes described in the strain description. Animals are typically ready to ship in 11-14 weeks. If a second recovery is required to produce the minimum number of animals, then delivery time would increase to approximately 25 weeks. If we fail to produce animals of the correct genotype, you will not be charged. We cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation.

Related Products and Services

Frozen Mouse Embryo

$2,595.00 per straw or vial

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

Terms Of Use

Terms of Use

General Terms and Conditions

Questions about Terms of Use

Additional Use Restrictions Apply

Use of MICE by companies or for-profit entities requires a license prior to shipping.

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

Credit for PRODUCTS or SERVICES

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Animal Care and Use for SERVICES

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Also Known As: Tsc1 flox, Tsc1c

Donating Investigator

Genetic overview

Research Applications

Base Price

Detailed Description

Development

Control Suggestions

Additional Information

Selected References

Tsc1tm1Djk

Allele Symbol: Tsc1tm1Djk

Disease Terms

Model with phenotypic similarity to human disease where etiologies are distinct. Human genes are associated with this disease. Orthologs of these genes do not appear in the mouse genotype(s).

Models with phenotypic similarity to human diseases where etiology is unknown or involving genes where ortholog is unknown.

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Mammalian Phenotype Terms by Genotype

Genotype: Tsc1tm1Djk/Tsc1tm1.1Djk Tg(Syn1-cre)671Jxm/0involves: 129S4/SvJae * C57BL/6 * CBA

behavior/neurological phenotype

cellular phenotype

growth/size/body region phenotype

mortality/aging

nervous system phenotype

skeleton phenotype

Genotype: Tsc1tm1Djk/Tsc1tm1Djk Tg(Syn1-cre)671Jxm/0involves: 129S4/SvJae * C57BL/6 * CBA

behavior/neurological phenotype

growth/size/body region phenotype

mortality/aging

nervous system phenotype

Genotype: Tsc1tm1Djk/Tsc1tm1Djkinvolves: 129S4/SvJae * C57BL/6

behavior/neurological phenotype

homeostasis/metabolism phenotype

liver/biliary system phenotype

Genotype: Tsc1tm1Djk/Tsc1tm1Djk Tg(Gdf9-icre)5092Coo/?involves: 129S4/SvJae * C57BL/6J

endocrine/exocrine gland phenotype

homeostasis/metabolism phenotype

reproductive system phenotype

Genotype: Tsc1tm1Djk/Tsc1tm1Djk Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+involves: 129S4/SvJae * C57BL/6 * DBA

homeostasis/metabolism phenotype

mammalian phenotype

liver/biliary system phenotype

Genotype: Tsc1tm1Djk/Tsc1tm1Djkinvolves: 129S4/SvJae

mammalian phenotype

Genotype: Tsc1tm1Djk/Tsc1+ Tg(Pcp2-cre)2Mpin/0involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/cJ * C57BL/6J

behavior/neurological phenotype

nervous system phenotype

Genotype: Tsc1tm1Djk/Tsc1tm1Djk Tg(Pcp2-cre)2Mpin/0involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/cJ * C57BL/6J

behavior/neurological phenotype

nervous system phenotype

References

Additional - Tsc1tm1Djk related

Genotyping Protocols

Dietary Information

Breeding Considerations

Mating System

Citation

Animal Health Reports

Live Mouse

Cryorecovery - Pricing

Related Products and Services

Payment Terms and Conditions

The Jackson Laboratory's Genotype Promise

Terms of Use

Additional Use Restrictions Apply

Licensing Information

JAX® Mice, Products & Services Conditions of Use

No Warranty

Credit for PRODUCTS or SERVICES

Animal Care and Use for SERVICES

No Liability

Also Known As: Tsc1 flox, Tsc1^c

Tsc1^tm1Djk

Allele Symbol: Tsc1^tm1Djk

Genotype: Tsc1^tm1Djk/Tsc1^tm1.1Djk Tg(Syn1-cre)671Jxm/0
involves: 129S4/SvJae * C57BL/6 * CBA

Genotype: Tsc1^tm1Djk/Tsc1^tm1Djk Tg(Syn1-cre)671Jxm/0
involves: 129S4/SvJae * C57BL/6 * CBA

Genotype: Tsc1^tm1Djk/Tsc1^tm1Djk
involves: 129S4/SvJae * C57BL/6

Genotype: Tsc1^tm1Djk/Tsc1^tm1Djk Tg(Gdf9-icre)5092Coo/?
involves: 129S4/SvJae * C57BL/6J

Genotype: Tsc1^tm1Djk/Tsc1^tm1Djk Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
involves: 129S4/SvJae * C57BL/6 * DBA

Genotype: Tsc1^tm1Djk/Tsc1^tm1Djk
involves: 129S4/SvJae

Genotype: Tsc1^tm1Djk/Tsc1⁺ Tg(Pcp2-cre)2Mpin/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/cJ * C57BL/6J

Genotype: Tsc1^tm1Djk/Tsc1^tm1Djk Tg(Pcp2-cre)2Mpin/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/cJ * C57BL/6J

Additional - Tsc1^tm1Djk related